# Ardelyx to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-in-upcoming-investor-conferences-15d358d0
Ticker: ARDX
Company: Ardelyx
Source: Ardelyx
Published: 2026-03-04 13:00 EST
## Summary

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and...

## Article Body
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:

Leerink Partners 2026 Global Healthcare Conference Location: Miami, FL Presentation: Tuesday, March 10 at 4:20 p.m. ET 1x1 Meetings: Tuesday, March 10

To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com . A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

Jefferies 2026 Biotech on the Beach Summit Location: Miami, FL 1x1 Meetings: Wednesday, March 11

About Ardelyx, Inc. Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL ® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter) , LinkedIn and Facebook .

Investor and Media Contacts: Caitlin Lowie clowie@ardelyx.com
## Recent Company News
- 2026-07-23 12:01 EST — [Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-report-second-quarter-2026-financial-results-on-august-6-2026-cf11d40a) — Source: Ardelyx
- 2026-05-19 12:01 EST — [Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-2026-a45950e8) — Source: Ardelyx
- 2026-05-07 12:01 EST — [Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings](https://biopharmsignal.com/news/ARDX/ardelyx-presents-analysis-supporting-long-term-safety-of-xphozah-at-nkf-s-spring-06ad1b71) — Source: Ardelyx
- 2026-04-30 20:01 EST — [Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARDX/ardelyx-reports-first-quarter-2026-financial-results-and-provides-business-updat-8ab879af) — Source: Ardelyx
- 2026-04-27 12:01 EST — [Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings](https://biopharmsignal.com/news/ARDX/ardelyx-announces-abstract-accepted-for-poster-presentation-at-the-nkf-s-spring--6ee5c2f6) — Source: Ardelyx
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)